(a)For the purposes of this subchapter , the term:
(1)"Commission" means the Opioid Abatement Advisory Commission established by § 7-3212 .
(2)"Evidence-based" means that an activity, practice, program, service, support, or strategy has undergone multiple randomized controlled trials and observational studies demonstrating that it helps individuals avoid the development and progression of opioid and other substance use disorders or drug-related harms, reduces the adverse consequences of opioid and other substance use, or manages, slows the progression of, or supports recovery from an opioid use disorder or co-occurring substance use or mental health disorder.
(3)"Evidence-informed" means an activity, practice, program, service, support, or strategy that incorporates the best a
Free access — add to your briefcase to read the full text and ask questions with AI
(a) For the purposes of this subchapter , the term:
(1) "Commission" means the Opioid Abatement Advisory Commission established by § 7-3212 .
(2) "Evidence-based" means that an activity, practice, program, service, support, or strategy has undergone multiple randomized controlled trials and observational studies demonstrating that it helps individuals avoid the development and progression of opioid and other substance use disorders or drug-related harms, reduces the adverse consequences of opioid and other substance use, or manages, slows the progression of, or supports recovery from an opioid use disorder or co-occurring substance use or mental health disorder.
(3) "Evidence-informed" means an activity, practice, program, service, support, or strategy that incorporates the best available evidence, patient needs, values, and preferences, and practitioner expertise into the decision-making process.
(4) "Fund" means the Opioid Abatement Fund established by § 7-3221 .
(5) "Harm reduction" means an activity, practice, program, service, support, or strategy that addresses both conditions that precede and occur as a result of substance use and attempts to reduce the adverse consequences of opioid and other substance use among persons who continue to use those substances.
(6) "Infrastructure" means the resources, such as personnel, buildings, or equipment, required for the District or another entity to provide evidence-based and evidence-informed harm reduction, prevention, recovery, and treatment activities, practices, programs, services, supports, and strategies to individuals with opioid use disorder and co-occurring substance use and mental health disorders.
(7) "Office" means the Office of Opioid Abatement established by § 7-3213 .
(8) "Prevention" means primary, secondary, and tertiary efforts to help individuals avoid the development and progression of opioid use disorder and co-occurring substance use and mental health disorders and drug-related harms.
(9) "Recovery" means a process through which an individual develops a healthier life, which may include:
(A) Improving the individual's quality of life, including the individual's physical and mental health;
(B) The individual's consistent pursuit of abstinence from the substances or behaviors that have negatively impacted them, their family, and their community;
(C) Relief of the individual's symptoms, including substance craving; and
(D) Improvement of the individual's relationships, social connectedness, and interpersonal skills.
(10) "Treatment" means:
(A) An evidence-based or evidence-informed activity, practice, program, service, support, or strategy to intervene upon, care for, manage, slow the progression of, or support recovery from opioid use disorder or co-occurring substance use or mental health disorders;
(B) That is individualized to address each individual's medical needs; and
(C) That includes screening for and diagnosis of substance use disorders or co-occurring mental or physical health disorders, as well as pharmacological and non-pharmacological therapeutic interventions for opioid use disorder or co-occurring substance use or mental health disorders.